Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 2
2007 1
2008 3
2009 3
2010 1
2013 5
2014 4
2015 1
2016 2
2017 1
2019 1
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
Aftimos P, Rolfo C, Rottey S, Barthélémy P, Borg C, Park K, Oh DY, Kim SW, De Jonge N, Hanssens V, Zwanenpoel K, Molthoff C, Vugts D, Dreier T, Verheesen P, van Dongen GAMS, Jacobs J, Van Rompaey L, Hultberg A, Michieli P, Pauwels P, Fung S, Thibault A, de Haard H, Leupin N, Awada A. Aftimos P, et al. Among authors: michieli p. Biomedicines. 2021 Jun 10;9(6):665. doi: 10.3390/biomedicines9060665. Biomedicines. 2021. PMID: 34200749 Free PMC article.
Four individually druggable MET hotspots mediate HGF-driven tumor progression.
Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P. Basilico C, et al. Among authors: michieli p. J Clin Invest. 2014 Jul;124(7):3172-86. doi: 10.1172/JCI72316. Epub 2014 May 27. J Clin Invest. 2014. PMID: 24865428 Free PMC article.
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.
Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. Van Schaeybroeck S, et al. Among authors: michieli p. Cell Rep. 2014 Jun 26;7(6):1940-55. doi: 10.1016/j.celrep.2014.05.032. Epub 2014 Jun 12. Cell Rep. 2014. PMID: 24931611 Free article.
29 results